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Oral tolerance is a promising approach for allergy prevention in early life, but it strongly 
depends on allergen exposure and proper immune environment. Small tolerance-induc-
ing peptides and dietary immunomodulatory components may comprise an attractive 
method for allergy prevention in at-risk infants. This study aimed to investigate whether 
early oral exposure to β-lactoglobulin-derived peptides (BLG-peptides) and a specific 
synbiotic mixture of short- and long- chain fructo-oligosaccharides (scFOS/lcFOS, FF) 
and Bifidobacterium breve (Bb) M-16V (FF/Bb) can prevent cow’s milk allergy (CMA). 
Three-week-old female C3H/HeOuJ mice were orally exposed to phosphate buffered 
saline (PBS), whey protein, or a mixture of four synthetic BLG-peptides combined with 
a FF/Bb-enriched diet prior to intragastric sensitization with whey protein and cholera 
toxin. To assess the acute allergic skin response and clinical signs of allergy, mice were 
challenged intradermally with whole whey protein. Serum immunoglobulins were ana-
lyzed after a whey protein oral challenge. Cytokine production by allergen-reactivated 
splenocytes was measured and changes in T cells subsets in the spleen, mesenteric 
lymph nodes, and intestinal lamina propria were investigated. Pre-exposing mice to a low 
dosage of BLG-peptides and a FF/Bb-enriched diet prior to whey protein sensitization 
resulted in a significant reduction of the acute allergic skin response to whey compared 
to PBS-pretreated mice fed a control diet. Serum immunoglobulins were not affected, 
but anaphylactic symptom scores remained low and splenocytes were non-responsive 
in whey-induced cytokine production. In addition, preservation of the Th1/Th2 balance in 
Abbreviations: BLG, β-lactoglobulin; CMA, cow’s milk allergy; CT, cholera toxin; ELISA, enzyme-linked immunosorbent 
assay; FF/Bb, specific synbiotic mixture of short- and long-chain fructo-oligosaccharides and Bifidobacterium breve M-16V; 
MLN, mesenteric lymph nodes; PBS, phosphate buffered saline; PepMix, mixture of four BLG-derived peptides; SCFA, short-
chain fatty acids; Th, T helper cells; Treg, regulatory T cells.
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the small intestine lamina propria was a hallmark of the mechanism underlying the pro-
tective effect of the BLG-peptides–FF/Bb intervention. Prior exposure to BLG-peptides 
and a FF/Bb-enriched diet is a promising approach for protecting the intestinal Th1/Th2 
balance and reducing the allergic response to whole whey protein. Therefore, it might 
have implications for developing successful nutritional strategies for CMA prevention.
Keywords: acute allergic skin response, dietary interventions, food allergy, mouse models, oral tolerance, 
peptides, prevention, T cells
inTrODUcTiOn
Food allergies are becoming a serious health concern worldwide. 
Cow’s milk allergy (CMA) is the most prevalent food allergy in 
infancy and the earliest to occur. Even though the majority of 
cow’s milk allergic infants outgrow their allergy (1), they are often 
affected by allergies to other foods, such as peanut; a phenomenon 
referred to as the “Food Allergic March” (2). CMA further plays 
an important role in the atopic march, meaning that early life 
CMA may predispose to inhalant-triggered hypersensitivity or 
asthma later in life (3).
Food allergy is suggested to occur due to defective oral toler-
ance (4). Oral tolerance is the process that actively suppresses the 
immune response to ingested harmless antigens (5, 6). Research 
is, therefore, focused on actively inducing or repairing oral toler-
ance. Studies in mice document that oral tolerance is a strongly 
antigen-dependent process (7), emphasizing the importance of 
antigen exposure in early life. Recent reports reveal that con-
sumption of peanuts by Jewish infants in Israel is associated with 
fewer occurrences of peanut allergy (8) and that feeding at-risk 
infants the allergenic food early in life can prevent food allergy 
development (9). However, exposure to the intact antigen might 
also result in sensitization or allergic symptoms development in 
infants at high risk of developing food allergy. To avoid this, oral 
tolerance approaches implementing allergen fragments can be 
used instead. For instance, partially hydrolyzed whey proteins 
were shown to suppress allergic symptoms to cow’s milk in mice 
(10). Even small immunogenic peptides containing T cell epitopes 
can be potent inducers of tolerance and may be a suitable alterna-
tive to whole protein antigens (11). Supplementing hydrolyzed 
formula with specific peptides was found effective in preventing 
the allergic response to the native protein (12). In follow-up 
studies, a reduced allergic sensitization to the major cow’s milk 
protein β-lactoglobulin (BLG) was observed when it was co-
administered with BLG-derived peptides (13). Meulenbroek et al. 
further reported that oral pre-exposure to synthetic BLG-derived 
peptides reduces the allergic skin response to whole whey pro-
tein (14). Altogether, these studies support the hypothesis that 
specific protein fragments may be suitable for allergen-specific 
immunomodulation.
Generic immunomodulation suggests the use of dietary 
components with beneficial immunomodulatory properties 
to support immune system maturation and natural oral toler-
ance development by providing the right environment for oral 
tolerance induction (15). Supplementing infant formulas with 
dietary prebiotics reduces the prevalence of atopic manifesta-
tions and induces bifidobacteria- and lactobacilli-predominating 
gut microbiota, resembling the situation in breast-fed infants 
(16–19). Bacterial dysbiosis, especially abnormal levels of bifi-
dobacteria, has been associated with increased risk of allergy 
(20,  21). Interestingly, non-digestible oligosaccharides, such as 
inulin and other fructo-oligosaccharides, are selectively utilized 
by bifidobacteria in both rats and humans (22) and increase 
gut bifidobacteria by 10-fold in healthy volunteers (23). Studies 
in rodents suggest the involvement of T helper 1 (Th1) and T 
regulatory (Treg) cells in the prevention of allergic asthma and 
cow’s milk allergic symptoms by dietary non-digestible oligo-
saccharides (24,  25). Combining fructo-oligosaccharides with 
a probiotic bacterial strain such as Bifidobacterium breve (Bb) 
M-16V (a concept known as synbiotics) might result in stronger 
immunomodulatory properties. The M-16V bacterial strain 
is known for its anti-allergic activity (26, 27) and has shown 
beneficial effects in infants with atopic dermatitis (28). Further, 
the use of synbiotic mixtures containing Bb M-16V was found 
effective in preventing CMA allergic symptoms (29, 30) as well as 
house dust mite-induced allergic asthma in mice (31). In a recent 
clinical trial with infant formulas, it was reported that children 
fed a formula containing fructo-oligosaccharides and Bb M-16V 
had an increased percentage bifidobacteria in their feces (32). 
Bb M-16V is suggested to enhance the homing process of naïve 
T cells to mesenteric lymph nodes (MLN), induce mucosal IgA 
production (33), and upregulate the TGF-β1 signaling (34), while 
they can partially modulate the TNF-α signaling in epithelial 
cells (35). Therefore, a dietary synbiotic mixture combining 
fructo-oligosaccharides and Bb M-16V is of interest for provid-
ing generic immunomodulation in preventive strategies for food 
allergy.
In this study, we assessed the potential of an early oral expo-
sure to a mixture of four synthetic BLG-derived peptides and a 
specific mixture of short- and long-chain fructo-oligosaccharides 
(scFOS/lcFOS, FF) and Bb M-16V (FF/Bb) to prevent allergy 
development in a murine model of orally induced CMA. We 
hypothesize that providing the right immune environment 
by means of a synbiotic diet during BLG-peptide presentation 
to immune cells would improve the capacity of the peptides to 
prevent allergic symptoms to the whole whey protein.
MaTerials anD MeThODs
Peptides
Four 18-AA-long peptides from the B variant of BLG were 
synthetically produced by JPT Peptide Technologies (Berlin, 
Germany). The four peptides contain a 12-AA-long overlap 
FigUre 1 | sequence information of the four synthetic peptides.
FigUre 2 | a schematic overview of the murine model for cow’s milk allergy prevention. CT, cholera toxin.
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(Figure 1) and were previously screened in human T cell lines 
and used in an animal model (14). The BLG-derived peptides 
were dissolved in sterile phosphate buffered saline (PBS; Lonza, 
Walkerville, MD, USA) and mixed until each peptide was at a 
concentration of 0.08 mg/mL (further referred to as PepMix).
Diets
Semi-purified cow’s milk protein-free standard mouse chow was 
composed according to a AIN-93G recipe (control diet) and sup-
plemented with 1% (wt:wt) of non-digestible scFOS (Raftilose 
P95, Beneo Orafti S.A., Oreye, Belgium) and lcFOS (Raftiline HP, 
Beneo Orafti S.A.) in a ratio 9:1 and 2% (wt:wt) 2 × 109 CFU/g 
Bb M-16V (Morinaga Milk Industry, Tokyo, Japan) (FF/Bb diet; 
Research Diet Services, Wijk bij Duurstede, The Netherlands). 
The synbiotic components were mixed through the diet and 
pressed into pellets. Diets were stored at 4°C prior to use.
animals
Three-week-old pathogen-free female C3H/HeOuJ mice were 
purchased from Charles River Laboratories (Sulzfeld, Germany). 
Mice were housed in the animal facility of Utrecht University. 
This study was carried out in accordance with the recommen-
dations of the Animal Ethics Committee of Utrecht University. 
The protocol was approved by the Animal Ethics Committee of 
Utrecht University (approval number DEC2014.II.12.100).
Oral Tolerance induction, sensitization, 
and challenge of Mice
Upon arrival, mice were fed the control or the FF/Bb diet ad libi-
tum for a period of 9 days (Figure 2). In the same week, mice 
were orally exposed (using a blunt needle) to 0.16 mg PepMix 
(0.04  mg of each BLG-derived peptide), 50  mg whey protein 
(DMV International, Veghel, The Netherlands), or PBS (0.5 mL) 
daily for 6 days. From day 0, all mice were maintained on control 
diet and sensitized as previously described (10). Five days after 
the last sensitization, an intradermal challenge was performed 
to assess the allergic response. Mice were challenged orally 
with 50 mg whey, followed by blood sampling at 2 h and blood 
sampling and sacrifice at 18  h after oral challenge. Serum was 
obtained and stored at −80°C until measurement.
evaluation of the allergic response
To measure the acute allergic skin response, mice were challenged 
intradermally in the ear pinnae with 10 µg whey protein per ear. 
Ear thickness was recorded before and 1 h after the intradermal 
challenge using a digital micrometer (Mitutoyo, Veenendaal, 
The Netherlands) and the acute skin response was calculated as 
Δ = ear thickness at 1 h − basal ear thickness and is expressed as 
delta micrometer. The anaphylactic shock symptoms were scored 
according to a previously described table (29).
allergen-specific immunoglobulins  
in serum
Serum whey- and BLG-specific immunoglobulins were quantified 
by means of an enzyme-linked immunosorbent assay (ELISA) as 
previously described (10), with few modifications. Briefly, high 
binding Costar 9018 plates (Corning Inc., New York, NY, USA) 
were coated with 20  µg/mL whey or BLG protein in carbon-
ate–bicarbonate coating buffer (Sigma-Aldrich, Zwijdrecht, The 
Netherlands) overnight at 4°C. Plates were washed, blocked for 
1  h with 0.5% bovine serum albumin (Sigma-Aldrich)/0.05% 
Tween-20 (Merck, Billerica, MA, USA) buffer, and serum samples 
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were incubated for 2 h at room temperature. After washing, 1 µg/
mL of biotin-labeled rat anti-mouse IgE, IgG1, or IgG2a detection 
antibody (BD Biosciences, San Jose, CA, USA) was incubated 
for 1.5  h. The plates were washed and incubated for 1  h with 
streptavidin-horse radish peroxidase (Sanquin, Amsterdam, The 
Netherlands), washed again and the reaction was developed with 
3,3′,5,5′-tetramethylbenzidine (TMB, Thermo Fisher Scientific, 
Waltham, MA, USA). The reaction was stopped with 2 M H2SO4, 
and absorbance was measured at 450 nm on a Benchmark plate 
reader (Bio-Rad, Veenendaal, The Netherlands).
short-chain Fatty acid (scFa) 
concentrations in cecum
Cecal content was collected and immediately frozen in liquid 
nitrogen. Samples were stored at −80°C until measurement. 
Concentration of acetic, propionic, and butyric acids were deter-
mined by means of gas chromatography as previously described 
(36), using 2-ethylbutyric acid as internal standard.
cell isolation from Tissues
Lymphocytes were isolated from spleen, MLN, and small intestine 
lamina propria. Spleens and MLN were crushed through 70 µm 
cell strainers. Splenocyte suspension was incubated with lysis 
buffer (8.3 g NH4Cl, 1 g KHC3O, and 37.2 mg EDTA dissolved 
in 1 L demi water and filter sterilized) to remove red blood cells 
and then resuspended in RPMI 1640, 10% fetal bovine serum 
and penicillin (100  U/mL)/streptomycin (100  µg/mL). For the 
isolation of the lamina propria cells, the small intestine was 
removed, cleared of Peyer’s patches, washed in cold PBS, opened 
longitudinally, and minced in 0.5-cm fragments. Samples were 
washed in Hank’s Balanced Salt Solution (HBSS; Invitrogen, Life 
Technologies, Carlsbad, CA, USA) containing 15  mM HEPES 
(Gibco, Life Technologies, Carlsbad, CA, USA), pH = 7.2 followed 
by 4 × 15-min incubations with HBSS supplemented with 15 mM 
HEPES, 5 mM Na2-EDTA, 10% fetal bovine serum, and penicillin 
(100 U/mL)/streptomycin (100 µg/mL), pH = 7.2. The fragments 
were washed in RPMI 1640, 5% fetal bovine serum and penicillin 
(100 U/mL)/streptomycin (100 µg/mL) and incubated 2 × 45 min 
with an enzyme solution containing 0.25 mg/mL Collgenase type 
VIII (Sigma-Aldrich). To collect the lamina propria cells, frag-
ments were vortexed for 10 s after each incubation and passed 
through a 70 µm cell strainer.
Flow cytometry of immune cells
Spleen, MLN, and small intestine lamina propria cells were resus-
pended in PBS/1% bovine serum albumin and incubated with 
anti-mouse CD16/CD32 (Mouse BD Fc Block; BD Pharmingen, 
San Jose, CA, USA) to block non-specific binding sites. For 
surface staining, cells were incubated with CD4-PerCp-Cy5.5, 
CD69-APC, CXCR3-PE, CD25-AlexaFluor488, CD69-PE-Cy7, 
CD11c-PerCp-Cy5.5, CD8α-PE, CD11b-PE-Cy7, CD103-APC, 
CD11b-PE, CD83-FITC, CD86-APC (eBiosciences, San Diego, 
CA, USA), T1ST2-FITC (MD Biosciences, St. Paul, MN, USA), or 
CX3CR1-AlexaFluor488 (R&D Systems, Oxon, UK). Viable cells 
were distinguished by means of a fixable viability dye eFluor® 780 
(eBioscience). For detecting transcription factors, cells were first 
fixed and permeabilized with Foxp3 Staining Buffer Set (eBio-
science) according to manufacturer’s protocol and then stained 
with Foxp3-APC and RorγT-PE antibodies (eBioscience). Results 
were collected with BD FACSCanto II flow cytometer (Becton 
Dickinson, Franklin Lakes, NJ, USA) and analyzed with FlowLogic 
software (Inivai Technologies, Mentone, VIC, Australia).
Ex Vivo restimulation assay and  
cytokine Production
Spleens were removed aseptically and single cell suspensions were 
obtained as described above. Splenocytes (6 × 105) were cultured 
either with medium or with 500 µg/mL whey protein for 5 days 
at 37°C, 5% CO2. Supernatants were collected and analyzed for 
IL-5, IL-13, IL-10, IL-17A, and IFN-γ by means of a Cytometric 
Bead Array Flex Set assay (BD Biosciences) following manufac-
turer’s instructions. Results were obtained with BD FACSCanto 
II flow cytometer and analyzed with FCAP v.3.0 software (Becton 
Dickinson).
statistical analysis
For all statistical analyses, GraphPad Prism 6.0c software for 
Macintosh (GraphPad Software, San Diego, CA, USA) was used. 
Anaphylactic shock scores and serum immunoglobulins were 
analyzed by Kruskal–Wallis test followed by Dunn’s post hoc test 
for seven pre-selected comparisons. All other data were analyzed 
by one-way ANOVA, followed by Bonferroni’s multiple compari-
son post hoc test for selected groups. SCFA data and splenocytes 
cytokine results were first LOG-transformed. For testing correla-
tions non-parametric Spearman correlation coefficient test was 
used. All data are presented as mean ± SEM of 4–8 animals per 
group. p < 0.05 was considered of statistical significance.
resUlTs
Prior exposure to Blg-Derived Peptides 
and FF/Bb Diet reduced the acute 
allergic skin response to Whey Protein
To study the capacity of early exposure to dietary components 
and/or BLG-peptides to prevent CMA, mice were first pretreated 
for six consecutive days, then orally sensitized to whey protein 
with cholera toxin as an adjuvant and finally challenged intrader-
mally with whey. Upon intradermal challenge with whey, PBS-
pre-exposed whey-sensitized (PBS/CT+Whey) allergic controls 
developed a significantly higher acute allergic skin response com-
pared to the sham-sensitized control mice (PBS/CT). However, 
administering PepMix while feeding mice the FF/Bb diet sig-
nificantly reduced the acute skin response compared to the PBS/
CT+Whey group fed the control diet (p < 0.05, Figure 3A). Prior 
exposure to the PepMix alone or feeding mice only the FF/Bb diet 
for 9 days was insufficient to prevent the allergic skin response. 
However, combining the FF/Bb diet with the PepMix pretreat-
ment, tended to improve its preventive capacity when compared 
to mice exposed to PepMix and fed the control diet (p = 0.0819). 
As a control for maximal oral tolerance induction, animals were 
FigUre 3 | allergic response to whey protein after intradermal exposure. Five days after the last sensitization, mice were challenged intradermally with whey 
and the acute allergic skin response (a) and anaphylactic shock (B) were determined. The two parameters were analyzed also in a correlation model (c). Data are 
presented as mean ± SEM; n = 4 in PBS/CT group and n = 6–8 in all other groups; *p < 0.05, ***p < 0.001, ****p < 0.0001; (a) was analyzed with one-way ANOVA 
followed by Bonferroni post hoc test for selected groups; (B) was analyzed with Kruskal–Wallis non-parametric test, followed by Dunn’s post hoc test for selected 
groups, and (c) was analyzed with non-parametric Spearman correlation coefficient test. CT, cholera toxin.
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pre-exposed to a high dose of whey protein prior to sensitization 
which resulted in the strongest reduction of the acute allergic 
skin response as expected (Figure 3A). PBS/CT+Whey allergic 
control mice fed the control diet during the pretreatment period, 
tended to develop more severe anaphylactic shock symptoms after 
intradermal whey challenge compared to the sham-sensitized 
controls (p = 0.0590) (Figure 3B). Mice administered the PepMix 
while fed the FF/Bb diet still experienced allergic symptoms but 
to a lesser extent. In line with this, the suppressed acute allergic 
skin response was found to correlate with less severe anaphylactic 
shock symptoms (Figure 3C).
Pretreatment with Blg-Peptides and 
FF/Bb Does not affect the Whey- or  
Blg-specific immunoglobulins
As type I food allergy is associated with increased levels of serum 
immunoglobulins (37), the effect of the pretreatments on whey- 
and BLG-specific immunoglobulin production was determined 
18 h after the oral challenge with whey protein (Table 1). Even 
though all immunoglobulins were elevated in the PBS/CT+Whey 
allergic control mice, only whey-specific IgE levels were sig-
nificantly elevated compared to the sham-sensitized control mice. 
BLG-specific IgE and IgG1 were elevated significantly compared 
to the whey-pretreated mice. Though not significantly reduced, 
the levels of BLG-IgE detected in the combined PepMix+FF/Bb 
group resembled the levels measured in the sham-sensitized 
controls.
FF/Bb increased the scFa levels  
in cecum
To monitor for changes in the microbiota, concentrations of 
SCFA in the cecum were determined as a measure of microbiota 
metabolic activity. PBS/CT+Whey allergic controls tended to 
have reduced butyric acid concentrations compared to sham-
sensitized control mice (p = 0.0529) and significant lower levels 
than the Whey-tolerized CT+Whey-sensitized controls. Feeding 
mice the FF/Bb diet for only 9 days prior to allergic sensitization 
resulted in increased SCFA concentrations in the gut after the 
5-week sensitization period compared to the PBS/CT+Whey 
allergic controls, reflecting that the diet possibly stimulated the 
microbiome metabolic activity. Prior exposure to FF/Bb not only 
prevented the drop in butyric acid but also increased acetic acid 
and tended to increase propionic acid concentrations (Figure 4).
combined exposure to PepMix and FF/Bb 
Prevented a Th1/Th2 Disbalance in the 
intestinal lamina Propria
In order to investigate the local effects in the intestine, the small 
intestine lamina propria lymphocytes were isolated and different 
T cell (Figure 5) and DC (Figure S1 in Supplementary Material) 
subsets were analyzed by flow cytometry. A tendency for higher 
percentage of Treg cells was observed in the PBS/CT+Whey aller-
gic mice fed the control diet compared to the sham-sensitized 
mice, while pretreatment with whole whey protein prevented 
this increase (Figure 5A). The frequency of activated Th17 cells 
did not differ between the sham-sensitized mice and the PBS/
CT+Whey allergic controls; however, feeding whey protein prior 
to sensitization resulted in a reduced percentage of activated Th17 
cells, and, similarly, pre-exposure to the FF/Bb diet with or with-
out PepMix tended to decrease the Th17 frequency. Furthermore, 
PBS/CT+Whey allergic mice had a lower frequency of activated 
Th1 cells, while the percentage of activated Th2 cells remained 
high (Figure 5B). As a result, the activated Th1/Th2 cell balance 
was shifted in favor of Th2 in these allergic mice. By contrast, 
prior oral exposure to PepMix and FF/Bb, similar to pretreat-
ment with whole whey protein, helped preserving the Th1/Th2 
balance. Feeding mice only the FF/Bb-supplemented diet tended 
to preserve the balance (p = 0.0715). When investigating the DC 
population in the small intestine lamina propria, no changes in 
the frequency of CD11c+ DC cells expressing the CD83 activa-
tion marker or the CD86 co-stimulatory molecule were observed 
(Figure S1A in Supplementary Material). Furthermore, the 
percentage of Th1 polarizing CD11b−CD8+ lymphoid DC or Treg 
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and Th2 polarizing CD11b+CD8a− myeloid DC (38–40) were not 
affected (Figure S1B in Supplementary Material). The higher per-
centage Treg cells in the PBS/CT+Whey group fed the control diet 
did not coincide with enhanced frequency of the Treg-inducing 
CD103+ DC (39, 41) (Figure S1C in Supplementary Material).
cytokine Production in spleen cells upon 
Whey stimulation is silenced by the 
combined exposure to PepMix and FF/Bb
To investigate whether the preventive treatments affect lympho-
cyte phenotype, spleen and MLN cells were analyzed by flow 
cytometry. Furthermore, splenocytes were stimulated ex vivo 
with allergen for 5  days to determine their allergen-induced 
cytokine profile as a measure of effect on cell functionality in 
the systemic compartment. In contrast to the local effects in the 
small intestine, lymphocyte phenotypes in the spleen and the 
MLN were not affected (Figure S2 in Supplementary Material). 
However, splenocytes from PBS/CT+Whey allergic mice mark-
edly increased the production of IL-13, IL-5, IL-10, IFN-γ, and 
IL-17A, while prior exposure to whole whey protein prevented 
this increase completely (Figure  6). Similarly, feeding mice a 
combination of PepMix and FF/Bb diet rendered splenocytes 
less responsive to ex vivo whole whey stimulation. Especially, 
it significantly reduced IL-10 (p  <  0.05). Also whey-induced 
production of IL-5, IL-13, IL-17A, and IFN-γ remained low and 
also tended to be reduced when compared to the PBS/CT+Whey 
allergic controls (p < 0.10 for all). Importantly, when compared 
to the PepMix treatment alone, the combination of PepMix and 
FF/Bb diet resulted in significantly lower IFN-γ, IL-17A, IL-10, 
IL-13, and IL-5 secretion (Figure 6).
DiscUssiOn
The present study demonstrates that a short pre-exposure to a 
low-dose mixture of four BLG-derived T cell epitopes was able 
to stimulate the development of oral tolerance to the major cow’s 
milk protein whey only when combined with a FF/Bb synbiotic 
diet. This oral tolerance was defined as the ability to reduce the 
acute allergic skin response after intradermal challenge with 
whole whey protein. Distinctive mechanistic features related to 
the preventive effect include the silencing of cytokine production 
upon ex vivo whole whey protein restimulation and the mainte-
nance of the intestinal Th1/Th2 balance.
The concept of using BLG-derived peptides for oral tolerance 
has previously been explored in animal models (12–14). In addi-
tion, synbiotics have been shown to alleviate allergic symptoms. 
However, in contrast to previous reports, this study focuses on 
(1) a short period of dietary intervention prior to sensitization 
and (2) low dose of a mixture of four short BLG-derived peptides 
for inducing tolerance to the whole whey protein. In our study, 
mice were exposed to the synbiotic diet only for 9 days before 
and not during the sensitization, while Schouten et al. provided 
the synbiotic diet 2 weeks prior to and continued throughout the 
sensitization period (29). Furthermore, in this study, a mixture 
of four specific BLG sequences was used for oral tolerance 
induction, while other studies co-administered BLG-peptides 
FigUre 4 | short-chain fatty acids (scFa) concentrations in cecum. On day 34, the cecum content was collected for measuring SCFA in supernatants. The 
absolute amount of acetic, propionic, and butyric acid is presented. Data are presented as mean ± SEM for n = 4 in PBS/CT group and n = 6–8 in all other groups. 
*p < 0.05, **p < 0.01 as analyzed with one-way ANOVA followed by Bonferroni post hoc test for selected groups after LOG transformation of the data. CT, cholera 
toxin.
FigUre 5 | T cell subsets in the small intestine lamina propria. Lymphocytes from the small intestine lamina proria were isolated and analyzed by flow 
cytometry for Treg and Th17 phenotype (a) or for Th1 and Th2 phenotype (B). Graphs illustrate the T cell subtypes as percentage of the CD4+ population and the  
Treg/Th17 and Th1/Th2 ratios within the CD4+ population. (c) Representative FACS plots for the percentages total Th1 and Th2 cells from the CD4+ population in 
sham-sensitized and whey-allergic mice as well as the percentages activated Th1 (CD69+CXCR3+) cells from the CD4+ in the same mice. Data are presented as 
mean ± SEM of n = 4 in the PBS/CT group and n = 6–8 in all other groups. *p < 0.05, **p < 0.01 as analyzed with one-way ANOVA followed by Bonferroni 
post hoc test for selected groups; CT, cholera toxin.
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FigUre 6 | impact on T cell function in the spleen. Ex vivo cytokine production by splenocytes after stimulation with allergen for 5 days. Data are presented as 
mean ± SEM of n = 4 in PBS/CT group and n = 6–8 in all other groups after subtracting the background cytokine levels. *p < 0.05, ***p < 0.001, ****p < 0.0001 as 
analyzed with one-way ANOVA followed by Bonferroni post hoc test for selected groups after LOG transformation of the data. CT, cholera toxin.
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combined with the whole BLG protein (13) or with BLG hydro-
lyzate (12). Only in one previous study, Meulenbroek et al. have 
documented a preventive effect of the BLG-derived peptides 
alone, but a 100-fold higher dose of the peptides was adminis-
tered compared to the dose used in the current study (14). Here, 
we report that pre-exposure to a much lower dose of BLG-derived 
peptides was able to reduce the acute allergic skin response to the 
whole whey protein only when combined with a FF/Bb dietary 
intervention. Therefore, supplementing a BLG-peptide-based 
preventive treatment with dietary synbiotics helps to reduce the 
amount of peptides needed to prevent the allergic response after 
whole whey sensitization. In addition to the dose, other factors, 
such as the frequency of administration, tolerogenic potency, 
and T cell receptor affinity, should be considered for optimizing 
the magnitude of oral tolerance induction and allergic response 
inhibition (11, 42).
Feeding the FF/Bb-enriched diet promoted the efficacy of 
the BLG-peptides and, therefore, emphasizes the importance of 
the proper immune environment during antigen presentation 
and oral tolerance induction in early life. Beneficial protective 
effects of the FF/Bb synbiotics have previously been shown in 
a murine model of allergic asthma (31). In CMA, Schouten 
et al. showed that dietary intervention with a similar synbiotic 
mixture, containing galacto- and fructo-oligosaccharides and 
Bb M-16V (GF/Bb), before and during sensitization with whey 
protein, was effective in preventing the allergic response in mice 
by improving the Th1 response (29, 43). This is in accordance 
with our data where combining the PepMix with FF/Bb diet 
supported the local preservation of the Th1/Th2 balance in the 
intestine. Furthermore, previous reports have documented that 
feeding inulin and other fructo-oligosaccharides positively 
influences the colonization of the gut with bifidobacteria (23). 
Even when combined in a synbiotic mixture with Bb M-16V, 
an increase in fecal bifidobacteria percentage was reported in 
infants (32). It is not excluded that the FF/Bb has influenced the 
colonization with bifidobacteria during the pre-exposure with 
peptides and in such way has contributed to providing more 
tolerance-prone environment. However, future studies need to 
explore the microbiota composition during the tolerance induc-
tion period. Furthermore, the exposure to the Bb M-16V via 
the diet might have contributed to a more tolerogenic and anti-
allergic environment by enhancing mucosal IgA production (33) 
and/or upregulating the TGF-β1 signaling in the gut (34). More 
in-depth studies are needed to confirm if these mechanisms are 
involved in the preventive effect of the combined PepMix-FF/Bb 
approach.
Dietary interventions with non-digestible oligosaccharides 
have been shown not only to affect the gut microbiota composi-
tion but also its metabolic activity (43). In the current study, 
mice were exposed to a FF/Bb-enriched diet for 9 days prior 
to sensitization and were fed a control diet during the 6-week 
sensitization period. After this period, increased levels of SCFA 
9Kostadinova et al. Synbiotics Support Tolerance by BLG Peptides
Frontiers in Immunology | www.frontiersin.org January 2017 | Volume 7 | Article 673
microbiota metabolites were measured in the cecum of mice 
fed the FF/Bb diet. However, butyrate levels were reduced in 
PBS/CT+Whey allergic mice fed the control diet and also in 
mice pretreated with PepMix and FF/Bb. Since PBS/CT+Whey 
allergic mice fed the control diet had significantly lower levels 
of butyrate compared to sham controls and whey-pretreated 
tolerant mice, this indicates that the allergic phenotype as such 
may reduce the butyrate levels in the mice. This may imply that 
the microbiome was changed or the metabolism of butyrate 
in the mucosal tissue was altered. The PepMix+FF/Bb-treated 
group, on the other hand, was successfully but only partially 
protected against the allergic sensitization which may relate to 
the lower butyrate levels observed in this group. This suggests 
the involvement of a preventive mechanism of PepMix+FF/Bb 
that is independent of the cecal butyric acid concentrations 
measured at the end of the experiment. Nevertheless, it is not 
excluded that the SCFA levels were differentially modulated 
during the PepMix+FF/Bb pretreatment period and this had 
contributed to the protective effect (44). However, further 
investigation needs to confirm this possibility. Most impor-
tantly, a short exposure to the FF/Bb diet  alone was not suf-
ficient to modulate the systemic allergen-specific response 
and to prevent the acute allergic response, emphasizing the 
importance of co-administering the peptides for oral tolerance 
induction to the antigen.
Pre-exposure to the combination of FF/Bb and BLG-peptides 
modulated the T cell responses to whole whey to a greater extend 
than the B cell responses. In a murine model of CMA, it was 
demonstrated that the whole whey protein was able to prevent 
both whey-specific immunoglobulins and allergic symptoms 
while the partially hydrolyzed protein was able to prevent the 
effector response only (10). Further, previous in vivo preventive 
studies with peptides (11, 12, 14) as well as therapeutic studies 
with peptide immunotherapy (42, 45), reported no effect on 
allergen-specific IgE levels in serum.
Main effector mechanisms of oral tolerance are active sup-
pression and T cell anergy/deletion (46). Low antigen doses may 
favor active suppression via regulatory cells while high antigen 
doses may favor T cell anergy/deletion; however, these mecha-
nisms are not mutually exclusive (47). In the current study, mice 
were exposed to a high dose of whey protein or to a low dose 
of PepMix combined with FF/Bb diet prior to sensitization. 
Strikingly, the results of those two treatments were very compa-
rable on the level of intestinal Th-cell balance and on the ex vivo 
whey-induced cytokine production of splenocytes. Feeding mice 
whole whey protein or PepMix+FF/Bb resulted in preservation 
of the homeostatic Th1/Th2 balance rather than expansion of 
Foxp3+ Treg cells. The local response in the intestine, however, 
suggested increased percentage of CD25+Foxp3+ T cells in the 
PBS/CT+Whey allergic mice that was reversed in the whey-
pretreated tolerant mice. This effect was, however, not coincided 
by increase in the Treg-inducing CD103+ DC subtype. Overall, no 
clear modulating effect on the different DC populations could 
be demonstrated at the end of the experiment. However, the 
late-phase at which the DC phenotyping is performed might 
not reflect the situation during the early induction phase where 
mice were fed the FF/Bb diet and given the BLG-peptides. In line 
with this, Hacini-Rachinel et al. reported a transient increase of 
ICOS+CD25+Foxp3+ T cells after 5 days of oral pre-exposure to 
egg protein which was detectable only within the first days after 
the last oral pre-exposure (48). It is, therefore, of importance 
to further examine the effects on DC and T cell differentiation 
directly after the tolerance induction period.
Cytokines are important mediators in sensitization and 
establishment of tolerance (49). The whey protein pretreatment 
alike Perrier et al.’s was found to prevent the allergen-induced 
production of Th2-associated cytokines as well as IL-17A and 
IFN-γ in whey-sensitized mice (49). Combining the BLG-
peptides treatment with the FF/Bb synbiotic diet silenced the 
allergen-induced cytokine production by splenocytes. This is 
in line with the cytokine suppression in peptide-induced toler-
ance described in previous studies (11, 50, 51). Importantly, 
the whey-induced cytokine production by splenocytes in the 
combined PepMix and FF/Bb group was significantly lower than 
in the group pretreated with BLG-peptides and fed the control 
diet. This underscores the essential contribution of the synbiotic 
diet in silencing of the allergen-specific T-cell response in mice 
exposed to PepMix. Furthermore, it highlights the importance 
of the right immune environment during oral tolerance induc-
tion with the low dose BLG-peptides which is crucial for the 
splenic non-responsiveness to whey re-exposure, potentially 
resulting from anergy. However, more in-depth investigation is 
necessary to confirm this mechanism for allergy prevention by 
BLG-peptides and FF/Bb.
In conclusion, this study demonstrated a reduction of the 
allergic response to the whole whey protein after a combined 
pre-exposure to only four synthetic BLG-derived peptides and 
a FF/Bb-enriched diet. The preventive effect of this combined 
pretreatment was associated with a preserved intestinal Th1/Th2 
balance and whey-induced non-responsiveness of splenocytes. 
Therefore, specific peptides and FF/Bb synbiotics may have 
implications as dietary supplementation for early life food 
allergy prevention. Further studies are needed to confirm the 
potential of this approach to prevent food allergy in at-risk 
infants.
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